Redwood AI’s Chemistry Engine Gets a Clinical Test in Non-Opioid Therapies

Redwood AI partners with Resilience Biosciences to apply computational chemistry and AI for developing non-opioid addiction treatments, aiming to accelerate early-stage drug discovery and reduce costs.

The race to shorten drug development cycles, which currently stretch beyond a decade and cost billions per new medicine, is pushing pharmaceutical firms to adopt artificial intelligence. Redwood AI Corp. is positioning its computational chemistry platform at the center of this shift, most recently through a collaboration with clinical-stage biotech Resilience Biosciences Inc. that targets a particularly urgent therapeutic area: non-opioid treatments for addiction and pain.

Resilience, headquartered in Vancouver, is developing therapies for opioid withdrawal, withdrawal-related pain, and cognitive deficits. The partnership, announced in May 2026, brings Redwood’s expertise in retrosynthesis, cheminformatics, and patent analysis to bear on the discovery of novel small-molecule drugs. Under the deal, Redwood will deploy its platform for systematic derivative generation, freedom-to-operate assessments, and synthesis planning — tasks that traditionally consume months of manual labor.

The technical scope is tightly defined. Redwood’s system combines in-silico synthesis planning with input from experienced medicinal chemists, enabling Resilience to explore chemical spaces more efficiently. The goal is to accelerate early-stage scientific analysis and produce drug-like molecules that are easier to develop, manufacture, and protect intellectually. “This cooperation strengthens the scientific and operational capabilities needed to support our growing portfolio of non-opioid programs,” said Resilience CEO Prof. Anthony Phillips, while Chief Operations Advisor Matthew Roberts described the deal as aligned with the firm’s long-term strategy.

The broader market backdrop lends weight to the collaboration. The global AI-driven drug discovery market is projected to exceed $50 billion by 2030, as the industry seeks to cut failure rates and compress timelines. For Redwood, the Resilience partnership is a high-stakes opportunity to demonstrate that its platform can move beyond theoretical promise and deliver tangible drug candidates.

Redwood has not rested on this deal alone. In the same month, it launched the Optimization Module for its Reactosphere platform, a tool that integrates Bayesian optimization, experimental design, and sampling planning into a single workflow. The module targets pharmaceuticals, materials science, specialty chemicals, and defense-related chemistry — broadening Redwood’s commercial footprint. Additionally, Innovate BC named Redwood one of the “Top 25 Investible Companies” in British Columbia, and the company presented at the Web Summit Vancouver in front of more than 700 international investors.

With the Resilience collaboration now in motion, attention turns to execution. The first joint drug candidates will test whether Redwood’s AI can deliver on its promise of faster, smarter lead identification. If successful, the partnership could open a significant revenue stream — and validate the company’s technology in a market hungry for alternatives to traditional drug discovery.